← Back to Search

Family Cognitive Behavioral Therapy for Obsessive-Compulsive Disorder

N/A
Recruiting
Led By S. Evelyn Stewart, MD
Research Sponsored by University of British Columbia
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Current DSM IV-TR Axis I diagnosis of childhood-onset OCD; Moderate to severe OCD (CY-BOCS≥16/40)
Male or female, aged 5-18 years old
Must not have
Current diagnosis of psychosis
Current diagnosis of bipolar disorder
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, midpoint, completion of 12 gf-cbt sessions, one-month follow-up
Awards & highlights
No Placebo-Only Group

Summary

This trial will evaluate a type of therapy to treat OCD in children, testing its effects on OCD symptoms and functioning compared to a control group. #OCD #CBT #FamilyTherapy

Who is the study for?
This trial is for children and teens aged 5-18 with Obsessive-Compulsive Disorder (OCD). They must speak English, have a moderate to severe form of OCD, and be able to give informed consent along with their parents. Those with bipolar disorder, psychosis, mental retardation, autism spectrum disorders or substance abuse issues cannot participate.
What is being tested?
The study tests Group-based Family Cognitive-Behavioral Therapy (GF-CBT) in treating pediatric OCD. Ninety participants will receive GF-CBT while another ninety on a waitlist serve as controls. The comparison focuses on changes in OCD severity and functioning after twelve GF-CBT sessions.
What are the potential side effects?
Since the intervention involves therapy rather than medication, typical medical side effects are not expected. However, participants may experience emotional discomfort or increased anxiety when confronting fears during CBT.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with severe childhood-onset OCD.
Select...
I am between 5 and 18 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have been diagnosed with psychosis.
Select...
I have been diagnosed with bipolar disorder.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, midpoint, completion of 12 gf-cbt sessions, one-month follow-up
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, midpoint, completion of 12 gf-cbt sessions, one-month follow-up for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Children's Yale Brown Obsessive-Compulsive Scale (CY-BOCS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Active Control
Group I: OCD-affected subjects (Group 1)Active Control1 Intervention
OCD-affected subjects will participate in 12 sessions of group therapy (as per GF-CBT protocol).
Group II: OCD-affected subjects (Group 2)Active Control1 Intervention
Waitlist affected-controls awaiting a treatment spot.

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor
1,466 Previous Clinical Trials
2,485,276 Total Patients Enrolled
Michael Smith Foundation for Health ResearchOTHER
19 Previous Clinical Trials
5,935 Total Patients Enrolled
S. Evelyn Stewart, MDPrincipal InvestigatorUniversity of British Columbia
3 Previous Clinical Trials
119 Total Patients Enrolled

Media Library

Group-based family cognitive-behavioural therapy Clinical Trial Eligibility Overview. Trial Name: NCT01635569 — N/A
OCD Research Study Groups: OCD-affected subjects (Group 1), OCD-affected subjects (Group 2)
OCD Clinical Trial 2023: Group-based family cognitive-behavioural therapy Highlights & Side Effects. Trial Name: NCT01635569 — N/A
Group-based family cognitive-behavioural therapy 2023 Treatment Timeline for Medical Study. Trial Name: NCT01635569 — N/A
~31 spots leftby Jun 2027